Intellectual Property
Sep. 4, 2015
Court’s ruling paves way for biosimilar sales
The U.S. Court of Appeals for the Federal Circuit denied a legal challenge Wednesday from Amgen Inc. to stop sales of Zarxio, the first so-called biosimilar approved by the federal government under a new law.
Daily Journal Staff Writer
The U.S. Court of Appeals for the Federal Circuit denied a legal challenge Wednesday
from Amgen Inc. to stop sales of Zarxio, the first so-called biosimilar approved by
the federal government under a new law aimed at regulating such products.
The result marks another win for Sandoz Inc., which secured U.S. Food and Drug Administrat...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In